Novartis Investigative Site

Logroño, La Rioja 26006

1 studies enrolling now · 4 studies all time

What they study most

Cardiovascular Disease, Heart Failure With Reduced Ejection Fraction (HF-rEF), Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Type 2 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early